Abbott Wins Approval for CATALYST Trial for At-Risk Stroke Patients

Lately, it seems as if Abbott Laboratories has been extremely busy building its structural heart offerings. The most recent example of this is the company winning FDA approval to conduct a new trial designed to assess the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder for people with atrial fibrillation (AFib).